Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:KALA NASDAQ:LSB NASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.07$2.37$1.58▼$9.22$49.53M0.52156,802 shs99,894 shsKALAKALA BIO$3.61$4.62$2.03▼$1,030.00$67.11M-2.4145,460 shs956,837 shsLSBLakeShore Biopharma$0.63$0.70$0.57▼$1.49$13.02M0.56202,885 shsN/AMREOMereo BioPharma Group$0.31$0.30$0.20▼$3.05$49.39M0.336.83 million shs1.44 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+2.48%-14.46%-12.29%-72.36%KALAKALA BIO0.00%+37.26%+38.85%-69.51%-98.30%LSBLakeShore Biopharma0.00%0.00%0.00%0.00%-35.36%MREOMereo BioPharma Group0.00%+1.44%+13.71%-9.53%-89.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.07$2.37$1.58▼$9.22$49.53M0.52156,802 shs99,894 shsKALAKALA BIO$3.61$4.62$2.03▼$1,030.00$67.11M-2.4145,460 shs956,837 shsLSBLakeShore Biopharma$0.63$0.70$0.57▼$1.49$13.02M0.56202,885 shsN/AMREOMereo BioPharma Group$0.31$0.30$0.20▼$3.05$49.39M0.336.83 million shs1.44 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+2.48%-14.46%-12.29%-72.36%KALAKALA BIO0.00%+37.26%+38.85%-69.51%-98.30%LSBLakeShore Biopharma0.00%0.00%0.00%0.00%-35.36%MREOMereo BioPharma Group0.00%+1.44%+13.71%-9.53%-89.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.50745.41% UpsideKALAKALA BIO 2.00Hold$1,018.7528,120.22% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/AMREOMereo BioPharma Group 2.25Hold$3.25950.42% UpsideCurrent Analyst Ratings BreakdownLatest LSB, KALA, ACTU, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/18/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.004/22/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/13/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.003/27/2026ACTUActuate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026KALAKALA BIO Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/23/2026MREOMereo BioPharma Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.34 per shareN/AKALAKALA BION/AN/AN/AN/A$12.56 per shareN/ALSBLakeShore Biopharma$85.67M0.15N/AN/A$3.35 per share0.19MREOMereo BioPharma Group$500K98.77N/AN/A$0.26 per share1.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$0.97N/AN/AN/AN/A-430.93%-180.86%N/AKALAKALA BIO-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/6/2026 (Estimated)LSBLakeShore Biopharma-$13.93MN/AN/AN/AN/AN/AN/AN/AN/AMREOMereo BioPharma Group-$41.88M-$0.05N/A15.47N/AN/A-81.28%-70.45%8/11/2026 (Estimated)Latest LSB, KALA, ACTU, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KALAKALA BIO-$8.50-$0.14+$8.36-$0.14N/AN/A5/14/2026Q1 2026ACTUActuate Therapeutics-$0.23-$0.24-$0.01-$0.24N/AN/A5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A4/15/2026Q4 2025KALAKALA BIO-$8.50$0.86+$9.36$43.00N/AN/A3/26/2026Q4 2025ACTUActuate Therapeutics-$0.24-$0.18+$0.06-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.801.80KALAKALA BION/A7.917.91LSBLakeShore Biopharma0.051.020.75MREOMereo BioPharma GroupN/A6.486.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AKALAKALA BIO24.61%LSBLakeShore Biopharma52.64%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%KALAKALA BIO2.24%LSBLakeShore BiopharmaN/AMREOMereo BioPharma Group6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.93 million10.05 millionN/AKALAKALA BIO3018.59 million18.17 millionNot OptionableLSBLakeShore Biopharma77320.77 millionN/AN/AMREOMereo BioPharma Group40159.62 million149.24 millionOptionableLSB, KALA, ACTU, and MREO HeadlinesRecent News About These Companies4basebio Announces Appointment of Chief Financial Officer and Board ChangesMay 14, 2026 | globenewswire.comMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comMereo BioPharma Group plc Sponsored ADRApril 19, 2026 | edition.cnn.comWe're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash WiselyApril 7, 2026 | finance.yahoo.comMREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc ...April 6, 2026 | gazettextra.comGClass Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & KorsinskyApril 6, 2026 | globenewswire.comMREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREOApril 6, 2026 | globenewswire.comMREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 6, 2026 | newsfilecorp.comNMEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their RightsApril 6, 2026 | globenewswire.comMREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026April 6, 2026 | businesswire.comMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOApril 6, 2026 | prnewswire.comMREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law FirmApril 6, 2026 | prnewswire.comMREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud LawsuitApril 5, 2026 | prnewswire.comMREO DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 5, 2026 | newsfilecorp.comNMREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026April 5, 2026 | newsfilecorp.comNMREO DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 4, 2026 | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmApril 3, 2026 | globenewswire.comMREO FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREOApril 3, 2026 | globenewswire.comMREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsApril 3, 2026 | businesswire.comMREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026April 3, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIntel Is the Market's Most Mispriced AI HedgeBy Jeffrey Neal Johnson | June 10, 2026Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?By Jessica Mitacek | June 1, 2026RTX Is Set to Revolutionize Munitions ManufacturingBy Jeffrey Neal Johnson | May 28, 20265 Best Growth Stocks for the Next 10 YearsBy Chris Markoch | May 31, 2026Workday Validates AI Flywheel: Stock Price Recovery BeginsBy Thomas Hughes | May 23, 2026LSB, KALA, ACTU, and MREO Company DescriptionsActuate Therapeutics NASDAQ:ACTU$2.07 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$2.15 +0.08 (+4.06%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.KALA BIO NASDAQ:KALA$3.61 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.57 -0.04 (-1.00%) As of 06/18/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.LakeShore Biopharma NASDAQ:LSBLakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Mereo BioPharma Group NASDAQ:MREO$0.31 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.32 +0.01 (+2.78%) As of 06/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
